Cargando…
Treatment-Resistant Epilepsy and Tuberous Sclerosis Complex: Treatment, Maintenance, and Future Directions
Tuberous sclerosis complex (TSC) is a neurogenetic disorder that affects multiple organ systems, including the heart, kidneys, eyes, skin, and central nervous system. The neurologic manifestations have the highest morbidity and mortality, in particular in children. Clinically, patients with TSC ofte...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083014/ https://www.ncbi.nlm.nih.gov/pubmed/37041855 http://dx.doi.org/10.2147/NDT.S347327 |
_version_ | 1785021420387958784 |
---|---|
author | Singh, Avantika Hadjinicolaou, Aristides Peters, Jurriaan M Salussolia, Catherine L |
author_facet | Singh, Avantika Hadjinicolaou, Aristides Peters, Jurriaan M Salussolia, Catherine L |
author_sort | Singh, Avantika |
collection | PubMed |
description | Tuberous sclerosis complex (TSC) is a neurogenetic disorder that affects multiple organ systems, including the heart, kidneys, eyes, skin, and central nervous system. The neurologic manifestations have the highest morbidity and mortality, in particular in children. Clinically, patients with TSC often present with new-onset seizures within the first year of life. TSC-associated epilepsy is often difficult to treat and refractory to multiple antiseizure medications. Refractory TSC-associated epilepsy is associated with increased risk of neurodevelopmental comorbidities, including developmental delay, intellectual disability, autism spectrum disorder, and attention hyperactivity disorder. An increasing body of research suggests that early, effective treatment of TSC-associated epilepsy during critical neurodevelopmental periods can potentially improve cognitive outcomes. Therefore, it is important to treat TSC-associated epilepsy aggressively, whether it be with pharmacological therapy, surgical intervention, and/or neuromodulation. This review discusses current and future pharmacological treatments for TSC-associated epilepsy, as well as the importance of early surgical evaluation for refractory epilepsy in children with TSC and consideration of neuromodulatory interventions in young adults. |
format | Online Article Text |
id | pubmed-10083014 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-100830142023-04-10 Treatment-Resistant Epilepsy and Tuberous Sclerosis Complex: Treatment, Maintenance, and Future Directions Singh, Avantika Hadjinicolaou, Aristides Peters, Jurriaan M Salussolia, Catherine L Neuropsychiatr Dis Treat Review Tuberous sclerosis complex (TSC) is a neurogenetic disorder that affects multiple organ systems, including the heart, kidneys, eyes, skin, and central nervous system. The neurologic manifestations have the highest morbidity and mortality, in particular in children. Clinically, patients with TSC often present with new-onset seizures within the first year of life. TSC-associated epilepsy is often difficult to treat and refractory to multiple antiseizure medications. Refractory TSC-associated epilepsy is associated with increased risk of neurodevelopmental comorbidities, including developmental delay, intellectual disability, autism spectrum disorder, and attention hyperactivity disorder. An increasing body of research suggests that early, effective treatment of TSC-associated epilepsy during critical neurodevelopmental periods can potentially improve cognitive outcomes. Therefore, it is important to treat TSC-associated epilepsy aggressively, whether it be with pharmacological therapy, surgical intervention, and/or neuromodulation. This review discusses current and future pharmacological treatments for TSC-associated epilepsy, as well as the importance of early surgical evaluation for refractory epilepsy in children with TSC and consideration of neuromodulatory interventions in young adults. Dove 2023-04-05 /pmc/articles/PMC10083014/ /pubmed/37041855 http://dx.doi.org/10.2147/NDT.S347327 Text en © 2023 Singh et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Singh, Avantika Hadjinicolaou, Aristides Peters, Jurriaan M Salussolia, Catherine L Treatment-Resistant Epilepsy and Tuberous Sclerosis Complex: Treatment, Maintenance, and Future Directions |
title | Treatment-Resistant Epilepsy and Tuberous Sclerosis Complex: Treatment, Maintenance, and Future Directions |
title_full | Treatment-Resistant Epilepsy and Tuberous Sclerosis Complex: Treatment, Maintenance, and Future Directions |
title_fullStr | Treatment-Resistant Epilepsy and Tuberous Sclerosis Complex: Treatment, Maintenance, and Future Directions |
title_full_unstemmed | Treatment-Resistant Epilepsy and Tuberous Sclerosis Complex: Treatment, Maintenance, and Future Directions |
title_short | Treatment-Resistant Epilepsy and Tuberous Sclerosis Complex: Treatment, Maintenance, and Future Directions |
title_sort | treatment-resistant epilepsy and tuberous sclerosis complex: treatment, maintenance, and future directions |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083014/ https://www.ncbi.nlm.nih.gov/pubmed/37041855 http://dx.doi.org/10.2147/NDT.S347327 |
work_keys_str_mv | AT singhavantika treatmentresistantepilepsyandtuberoussclerosiscomplextreatmentmaintenanceandfuturedirections AT hadjinicolaouaristides treatmentresistantepilepsyandtuberoussclerosiscomplextreatmentmaintenanceandfuturedirections AT petersjurriaanm treatmentresistantepilepsyandtuberoussclerosiscomplextreatmentmaintenanceandfuturedirections AT salussoliacatherinel treatmentresistantepilepsyandtuberoussclerosiscomplextreatmentmaintenanceandfuturedirections |